Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Novo Nordisk (NVO): In 2023, Novo Nordisk announced the results from its SELECT trial that showed that semaglutide was associated with a 20% decreased risk of major adverse cardiac events comprised of cardiovascular death, nonfatal myocardial infarction (MI), and stroke compared with placebo in patients with overweight or obesity and established CVD but without diabetes
Research Use Disclaimer This product is intended strictly for laboratory research and analytical purposes only
This treatment may be self-administered in the comfort of the patients own home or at either our Somerville or Florham Park office
The 5-on/2-off schedule is the most common community pattern
US$ 26.85
US$ 28.22
US$ 28.46
US$ 29.13
US$ 25.95
US$ 29.42
US$ 22.66
US$ 20.13
